Immuron Limited · ASX:IMC
Immuron — AusBiotech Invest 2025
14 slides from Immuron's conference presentation, Oct 21, 2025
Slide 1: AusBiotech Invest 2025
A Crown Towers INVEST > eLBOURNE HEALTH — 21,0ct 2025 VW AusBiotech Invest 2025 IMMUroNn @AusBiotechInvest #AusBiotechInvest2025 #ABI25 sia
Slide 2: Immuron company overview
a) —INVEST i: Crown Towers AusBiotech rg IMMUN ae ee Invest 2025 Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases. Immuron has three commercial product
Slide 3: Management and board
aul Brennan Prof. Ravi Savarirayan Director Former CEO of Polynovo (ASX:PNV), (2015- 2021): market cap. $30M to peak of $2B Clinical geneticist; Professor and Research IMMUreNn Steven Lydeamore Chief Executive Officer Group Leader (Skeletal Biology and Disease) at the Murdoch Children’s Research Ins
Slide 4: FY25 Financial Summary
FY25 Financial Summary Global Sales Revenue $7.3m Up 49% Australian Sales Revenue $5.3m Up 40% North American Sales Revenue $2.0m Up 76% Gross Profit Margin 65.4% EBITDA (ex - R&D) 1 $(3.1)m $2.1m improvement Cash + Term Deposit $5.9m (excludes A$2.8m raised from the US placement) 2 1 ex - R&D: add
Slide 5: Travelan continued strong sales growth
Travelan ® continued strong sales growth Global + FY2025 AUD$7.3 million up 49% on prior year + FY2026 Q1 AUD$2.0 million up 34% on FY2025 Q1 Australia + FY2025 AUD$5.2 million up 40% on prior year + FY2026 AUD$1.6 million up 52% on FY2025 Q1 North America + FY2025 AUD$2.0 million up 76% on prior ye
Slide 6: Proprietary technology platform and bovine colostrum
+ Reduce occurrence and reduce/relieve diarrhoea + Reduce/relieve abdominal cramping + Reduce/relieve gastrointestinal pain + Assists repair of gastrointestinal/gut wall lining + Enhance/promote immune defence + Enhance/promote health liver function Step 1 Australian Permitted indications; these sta
Slide 7: Pipeline and Key Milestones
2H 2025 2026 2027 2028 202G Traveller's Diarrhoea Travelan® US$ 102 m Uniformed Services University 100% of 851 participants recruited Topline Data IMM - 124E Completed End of Phase 2 FDA meeting; Phase 3 Phase 3 Phase 3; FDA review FDA approval Clostridioides Difficile IMM - 529 US$ 400 m IND submi
Slide 8: Traveller's Diarrhoea
iy) AusBiotech” Traveller's INVEST in Invest 2025 Diarrhoea IMMUreNn * Caused by consuming food or water infected with pathogens. Three or more unformed stools in 24 hours. * Bacterial pathogens are the predominant risk?. Enterotoxigenic E. coli (ETEC) are the predominant pathogens. * While antibiot
Slide 9: Travelan protection mechanism
uy AusBiotech ® — INVEST in Gi ales? nest 2025 ee IMMUN ees as * Travelan® offers proactive prevention, clinically proven to provide up to 90% protection.! This natural solution, enriched with anti-E. coli antibodies, reduces the risk of digestive issues before they arise.t Unlike other products tha
Slide 10: Clostridioides Difficile Infection
Clostridioides Difficile Infection
Slide 11: IMM-529 for recurrent C. difficile infection
IMMUreNn Indication / Target IMM-529 will be indicated for the treatment of recurrent C. difficile infection Population Product Description 7 * Novel antibody-containing therapeutic which neutralizes C. difficile but does not impact the Mechanism of Action microbiome * Targets not only toxin B but a
Slide 12: Commercial opportunity assessment for IMM-124E and IMM-529
› Immuron’s development of IMM - 124E (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need › Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demonstrating > 80 % protection against the development of diarrhea . › If
Slide 13: Global Biotech with Real-World Impact
y) Maseictechia © — INVEST iv viet gouRNe Invest 2025 Immur On HEALTH | . Global Biotech with Real-World Impact Immuron is one of the few ASX-listed biopharma companies with both commercialised products and a USS. dual listing (NASDAQ: IMRN). With a global footprint spanning Australia, the U.S., and
Slide 14: Contact information
p | IMMUroNn STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM % PHONE: AUSTRALIA: +61 438 027 172 @AusBiotechInvest #AusBiotechinvest2025 #ABI25